These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22371414)

  • 1. Fingolimod-associated macular edema: incidence, detection, and management.
    Jain N; Bhatti MT
    Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
    JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of fingolimod-associated macular edema.
    Chui J; Herkes GK; Chang A
    JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612
    [No Abstract]   [Full Text] [Related]  

  • 14. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does fingolimod in multiple sclerosis patients cause macular edema?
    Turaka K; Bryan JS
    J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A; Montalban X
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.